Literature DB >> 24058178

Double deficiency for RORγt and T-bet drives Th2-mediated allograft rejection in mice.

Manije Sabet-Baktach1, Elke Eggenhofer, Jordi Rovira, Philipp Renner, Margareta Lantow, Stefan A Farkas, Muriel Malaisé, Karoline Edtinger, Zhou Shaotang, Gudrun E Koehl, Marc H Dahlke, Hans J Schlitt, Edward K Geissler, Alexander Kroemer.   

Abstract

Although Th1, Th2, and Th17 cells are thought to be major effector cells in adaptive alloimmune responses, their respective contribution to allograft rejection remains unclear. To precisely address this, we used mice genetically modified for the Th1 and Th17 hallmark transcription factors T-bet and RORγt, respectively, which allowed us to study the alloreactive role of each subset in an experimental transplant setting. We found that in a fully mismatched heterotopic mouse heart transplantation model, T cells deficient for T-bet (prone to Th17 differentiation) versus RORγt (prone to Th1 differentiation) rejected allografts at a more accelerated rate, indicating a predominance of Th17- over Th1-driven alloimmunity. Importantly, T cells doubly deficient for both T-bet and RORγt differentiated into alloreactive GATA-3-expressing Th2 cells, which promptly induced allograft rejection characterized by a Th2-type intragraft expression profile and eosinophilic infiltration. Mechanistically, Th2-mediated allograft rejection was contingent on IL-4, as its neutralization significantly prolonged allograft survival by reducing intragraft expression of Th2 effector molecules and eosinophilic allograft infiltration. Moreover, under IL-4 neutralizing conditions, alloreactive double-deficient T cells upregulated Eomesodermin (Eomes) and IFN-γ, but not GATA-3. Thus, in the absence of T-bet and RORγt, Eomes may salvage Th1-mediated alloimmunity that underlies IL-4 neutralization-resistant allograft rejection. We summarize that, whereas Th17 cells predictably promote allograft rejection, IL-4-producing GATA-3(+) Th2 cells, which are generally thought to protect allogeneic transplants, may actually be potent facilitators of organ transplant rejection in the absence of T-bet and RORγt. Moreover, Eomes may rescue Th1-mediated allograft rejection in the absence of IL-4, T-bet, and RORγt.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24058178     DOI: 10.4049/jimmunol.1301741

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  T-bet expression by Th cells promotes type 1 inflammation but is dispensable for colitis.

Authors:  J Zimmermann; A A Kühl; M Weber; J R Grün; J Löffler; C Haftmann; R Riedel; P Maschmeyer; K Lehmann; K Westendorf; M-F Mashreghi; M Löhning; M Mack; A Radbruch; H D Chang
Journal:  Mucosal Immunol       Date:  2016-02-17       Impact factor: 7.313

2.  Differential modulation of IL-12 family cytokines in autoimmune islet graft failure in mice.

Authors:  Feng-Cheng Chou; Heng-Yi Chen; Hsin-Hui Chen; Gu-Jiun Lin; Shih-Hua Lin; Huey-Kang Sytwu
Journal:  Diabetologia       Date:  2017-09-19       Impact factor: 10.122

3.  Characterization of eomesodermin and T-bet expression by allostimulated CD8+ T cells of healthy volunteers and kidney transplant patients in relation to graft outcome.

Authors:  A Perez-Gutierrez; D M Metes; L Lu; S Hariharan; A W Thomson; M B Ezzelarab
Journal:  Clin Exp Immunol       Date:  2018-09-23       Impact factor: 4.330

4.  T-bet, but not Gata3, overexpression is detrimental in a neurotropic viral infection.

Authors:  Fumitaka Sato; Eiichiro Kawai; Nicholas E Martinez; Seiichi Omura; Ah-Mee Park; Satoru Takahashi; Keigyou Yoh; Ikuo Tsunoda
Journal:  Sci Rep       Date:  2017-09-05       Impact factor: 4.379

Review 5.  Old game, new players: Linking classical theories to new trends in transplant immunology.

Authors:  Marina Burgos da Silva; Flavia Franco da Cunha; Fernanda Fernandes Terra; Niels Olsen Saraiva Camara
Journal:  World J Transplant       Date:  2017-02-24

Review 6.  Regulatory B cells: an exciting target for future therapeutics in transplantation.

Authors:  Alexandre Nouël; Quentin Simon; Christophe Jamin; Jacques-Olivier Pers; Sophie Hillion
Journal:  Front Immunol       Date:  2014-01-22       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.